TANGO - towards faster prognosis of Alzheimer's and Parkinson's diseases?September 13, 2004A large number of diseases - including Alzheimer's disease, Parkinson's disease, and mad cow disease - are the result of proteins that erroneously assume the wrong shape, causing them to stick to each other. This phenomenon is perceptible, but up to now it has been difficult to predict. Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at the Free University of Brussels (VUB), in collaboration with a German research group, have developed TANGO - a statistical method that can predict the susceptibility of proteins to sticking together. Thus, for the first time, TANGO enables the prediction of risky protein alterations that underlie this group of diseases. When protein structure goes awry All living creatures, including humans, are made up of cells, and the vital functions within these cells are executed by proteins. The hereditary information for the production of proteins - including, among other things, their structure and length - is contained in our genes. But in order to be able to function properly, a protein must also fold itself correctly into its 3-dimensional structure. Sometimes this goes wrong and the proteins stick together, making them toxic and causing diseases like Alzheimer's. TANGO makes prediction of faulty protein structures possible Until recently, it was always thought that proteins stick together arbitrarily. But now it has become clear that a universal mechanism lies behind this process. Certain structural characteristics in proteins determine their susceptibility to sticking together. Using this information, Joost Schymkowitz and Frederic Rousseau have developed TANGO, a mathematical algorithm that looks at a large amount of data - including alterations of the protein and environmental factors - to indicate the degree of probability that particular proteins will stick together. TANGO thus opens possibilities for new diagnostic techniques for diseases that are caused by proteins that stick together erroneously. The VIB researchers also expect that TANGO will enable more efficient production of proteins for medical or industrial applications. The yield of these production processes is often low, because the proteins stick to each other and are therefore difficult to purify. With TANGO, one can determine under what conditions the solubility of the therapeutic proteins is large enough to purify them easily. Relevant scientific publications On 12 September, Schymkowitz and Rousseau's research was published online on the website of the authoritative journal, Nature Biotechnology (www.nature.com/nbt) Fernandez-Escamilla et al. Given that this research can raise a lot of questions for patients, we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address. VIB - Flanders Interuniversity Institute for Biotechnology |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||